Celularity Inc.

Celularity Inc. is a clinical and commercial stage biotechnology company headquartered in Florham Park, New Jersey, focused on regenerative and cellular medicine. The company's core business involves developing and manufacturing allogeneic and autologous cell therapies derived from the postpartum placenta. Its mission is to lead the next evolution in cellular medicine by delivering off-the-shelf allogeneic cellular therapies at unparalleled scale, quality, and economics, leveraging the unique biology of the postpartum placenta to create transformative therapies targeting aging, age-related diseases, and human performance.

Celularity's key products and services include off-the-shelf placental-derived allogeneic cell therapies, such as mesenchymal-like adherent stromal cells (MLASCs), Natural Killer (NK) cells, and engineered T cells (including CAR-T cells). These therapies are designed to address indications across cancer, immunologic, infectious, degenerative, and age-related diseases. The company also develops advanced biomaterial products derived from structural tissue components of the postpartum placenta, including products like Biovance, Interfyl, and CentaFlex. Celularity operates through distinct business segments, including Cell Therapy, Degenerative Disease, and BioBanking.

Robert J. Hariri, M.D., Ph.D., serves as the Founder, Chairman, and Chief Executive Officer of Celularity. In recent news, Celularity Inc. regained compliance with Nasdaq listing requirements on May 1, 2026, after filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. This achievement followed strategic actions, including the out-licensing of its biomaterials portfolio and a reduction in recorded liabilities, aimed at sharpening its strategic focus and strengthening its balance sheet. The company also recently closed a transaction with NexGel, involving the sale of certain commercial assets from its biomaterials product portfolio.